AlphAIAlphAI — Financial news for AI agents
stocktitan.net$ANGO

AngioDynamics Q1 FY2027 net loss narrows to $7.1M

AngioDynamics (NASDAQ: ANGO) reported Q1 FY2027 net loss of $7.1M, down from $10.9M YoY. Net sales rose 6.9% to $80.9M, with Med Tech sales up 13.2%. Adjusted EBITDA was $5.0M. The company announced Eric Honroth as new CEO, effective November 2, 2026. FDA approved IDE for RELIEF study on NanoKnife IRE for benign prostatic hyperplasia. Guidance reiterated: net sales $336M-$341M, adjusted EBITDA $13M-$16M.

Original reporting
stocktitan.net
Published Oct 8, 2026, 11:17 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 11:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ANGO
Bullish
high confidence
Mentioned
$ANGO
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ANGOBullishHigh
01

Why it matters

Earnings beat loss expectations and reaffirmed guidance, supporting a modest price rally; CEO transition and FDA IDE may add longer‑term upside.

02

Market read

First‑quarter earnings and guidance for a mid‑cap med‑tech firm; relevant for healthcare sector traders.

03

What to watch

Tariff refunds boosted margin this quarter and may not recur, potentially dampening future profitability.

Relevance 8/10Novelty 8/10Timing: immediate release

Background

AngioDynamics announced Q1 FY2027 results, highlighted Med Tech growth, new CEO appointment, and FDA IDE approval for a prostate study.

Company-level read

Ticker impact

$ANGOBullishHigh confidence
Context

Q1 FY2027 earnings released with narrowed net loss, adjusted EBITDA of $5M and reaffirmed FY guidance.

Expected impact

potential modest upside as market prices in improved loss profile and steady guidance

Evidence & confidence

Loss per share narrowed to $0.17 from $0.26 YoY and adjusted EBITDA more than doubled, indicating operational improvement.

Market effects

Sector

MedTech segment shows double‑digit growth, may lift peer valuations in vascular and oncology device space.

Regional

U.S. small‑cap healthcare sector could see slight lift.

Global

Limited to investors focused on U.S. med‑tech equities.

Counterpoint

What could challenge this read

Guidance unchanged despite narrowing loss may signal limited upside; investors could stay cautious.

Key entities

  • person
    Eric Honroth

    New President and CEO effective Nov 2 2026.

  • regulator
    FDA

    Granted IDE approval for RELIEF study of NanoKnife IRE.

Read at source← All news

StoryAngioDynamics posts Q1 FY2027 earnings beat and names new CEO

Also covered by

4 outlets

Related articles

$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife IRE for Prostate and Liver Cancer

AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to include NanoKnife IRE for prostate and liver cancer, effective October 1, 2026. This follows recent reimbursement milestones, including new CPT codes and Palmetto GBA's LCD L40205. Humana, with 7 million members, will use LCD L40205 criteria for coverage, subject to prior authorization.

marketscreener.com
$ANGOMed

H.C. Wainwright cuts AngioDynamics stock price target to $18

H.C. Wainwright reduced its price target for AngioDynamics (ANGO) to $18 from $19, maintaining a Buy rating. The company reported fiscal Q1 2027 net sales of $80.9M, up 6.9% YoY, but a net loss of $7.1M. Guidance for fiscal 2027 includes revenue of $336M-$341M and adjusted EBITDA of $13M-$16M. Canaccord Genuity reiterated its Buy rating with a $20 target, citing growth in key platforms. The stock fell 23% post-earnings.

investing.com
$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Polic

AngioDynamics (ANGO) announced Humana's updated Medicare Advantage coverage policy for its NanoKnife System, effective October 1, 2026. The policy applies LCD L40205 criteria for IRE technology, covering eligible patients with intermediate-risk prostate cancer and certain liver tumors. This follows recent reimbursement milestones, including CPT codes and Palmetto GBA's LCD. Humana, with 7 million members, will use LCD L40205 criteria for consistent coverage.

gurufocus.com
$ANGOHigh

AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics (ANGO) reported Q1 2027 revenue growth of 7%, with the MedTech segment up 13%. Auryon saw 14.7% growth, marking 21 consecutive quarters of double-digit gains. AlphaVac revenue rose 37.4% year-over-year. The company named Eric Honer as its new CEO, effective November 2. NanoKnife received FDA approval for a BPH study, targeting a $1.9B market. Med Device segment grew 1.4%.

finance.yahoo.com